Literature DB >> 15039235

Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model.

Peter R Durie1, Geraldine Kent, M James Phillips, Cameron A Ackerley.   

Abstract

The lack of an appropriate animal model with multiorgan pathology characteristic of the human form of cystic fibrosis has hampered our understanding of the pathobiology of the disease. We evaluated multiple organs of congenic C57BL/6J cystic fibrosis transmembrane regulator (Cftr)(-/-) and Cftr(+/+) mice maintained from weaning on a liquid diet then sacrificed between 1 and 24 months of age. The lungs of the Cftr(-/-) animals showed patchy alveolar overdistention, interstitial thickening, and fibrosis, with progression up to 6 months of age. The proximal and distal airway surface was encased with mucus-like material but lacked overt evidence of chronic bacterial infections or inflammation. All Cftr(-/-) animals showed progressive liver disease, with hepatosteatosis, focal cholangitis, inspissated secretions, and bile duct proliferation; after 1 year of age there was progression to focal biliary cirrhosis. The intercalated, intralobular and interlobular ducts and acinar lumina of the exocrine pancreas, the parotid and submaxillary glands of the Cftr(-/-) animals were dilated and filled with inspissated material, as well as mild inflammation and acinar cell drop out. Quantitative measurements of the pancreas showed significant acinar atrophy and increased acinar volume in comparison with age-matched Cftr(+/+) littermates. The ileal lumen and crypts were filled with adherent fibrillar material. After 3 months of age the vas deferens of the Cftr(-/-) animals could not be identified. None of the aforementioned pathological changes were observed in the Cftr(+/+) littermates fed the same liquid diet. We show, for the first time, that long-lived C578L/6J Cftr(-/-) mice develop manifestations of cystic fibrosis-like disease in all pathologically affected organs in the human form of cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039235      PMCID: PMC1615340          DOI: 10.1016/S0002-9440(10)63234-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases.

Authors:  E H Oppenheimer; J R Esterly
Journal:  Perspect Pediatr Pathol       Date:  1975

2.  The pathological changes in the liver in cystic fibrosis of the pancreas.

Authors:  J M CRAIG; H HADDAD; H SHWACHMAN
Journal:  AMA J Dis Child       Date:  1957-04

3.  Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice.

Authors:  U Sajjan; G Thanassoulis; V Cherapanov; A Lu; C Sjolin; B Steer; Y J Wu; O D Rotstein; G Kent; C McKerlie; J Forstner; G P Downey
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Early detection of pulmonary function abnormalities in cystic fibrosis.

Authors:  A Lamarre; B J Reilly; A C Bryan; H Levison
Journal:  Pediatrics       Date:  1972-08       Impact factor: 7.124

5.  The distribution and structure of cells in the tracheal epithelium of the mouse.

Authors:  R J Pack; L H Al-Ugaily; G Morris; J G Widdicombe
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

6.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

7.  G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages.

Authors:  G R Thomas; E A Costelloe; D P Lunn; K J Stacey; S J Delaney; R Passey; E C McGlinn; B J McMorran; A Ahadizadeh; C L Geczy; B J Wainwright; D A Hume
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

8.  Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants.

Authors:  J R Imrie; D G Fagan; J M Sturgess
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

9.  The visibly fatty liver.

Authors:  N T Griscom; M A Capitanio; M L Wagoner; G Culham; L Morris
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

10.  Parotid gland function in children with cystic fibrosis and child control subjects.

Authors:  J Blomfield; A R Rush; H M Allars; J M Brown
Journal:  Pediatr Res       Date:  1976-06       Impact factor: 3.756

View more
  62 in total

1.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

2.  Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Authors:  Mark Bazett; Lisa Honeyman; Anguel N Stefanov; Christopher E Pope; Lucas R Hoffman; Christina K Haston
Journal:  Mamm Genome       Date:  2015-02-27       Impact factor: 2.957

3.  Cystic fibrosis mice rehabilitated for studies of airway gland dysfunction.

Authors:  Hugo R de Jonge
Journal:  J Physiol       Date:  2007-02-22       Impact factor: 5.182

4.  Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice.

Authors:  Juan P Ianowski; Jae Young Choi; Jeffrey J Wine; John W Hanrahan
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

5.  Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis (CF).

Authors:  Charles N Falany; Dongning He; Li Li; Josie L Falany; Teresa W Wilborn; Thomas A Kocarek; Melissa Runge-Morris
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03-03       Impact factor: 4.292

Review 6.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

7.  Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice.

Authors:  Elise Bonvin; Philippe Le Rouzic; Jean-François Bernaudin; Charles-Henry Cottart; Clarisse Vandebrouck; Antoine Crié; Teresinha Leal; Annick Clement; Monique Bonora
Journal:  J Physiol       Date:  2008-05-01       Impact factor: 5.182

Review 8.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 9.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

10.  Ceramide mediates lung fibrosis in cystic fibrosis.

Authors:  Regan Ziobro; Brian Henry; Michael J Edwards; Alex B Lentsch; Erich Gulbins
Journal:  Biochem Biophys Res Commun       Date:  2013-03-21       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.